| abstract |
Compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar?1 and Ar2¿ are optionally substituted heteroaryl or optionally substituted phenyl; X1 is -O-, -S-, -SO-, -SO¿2?-, -NR?12¿-, -NCOR12- or -NR12SO2R15; (a) is selected from the group consisting of (b), (c), (d) and (e); X2 is -O-, -S- or -NR5-; Y is =O, =S or =NR11; Y1 is H, C¿1?-C6 alkyl, -NR?17R13¿, -SCH¿3, R?19-aryl(CH¿2?)n6-, R?19¿-heteroaryl-(CH¿2?)n6-, -(CH2)n6-heterocycloalkyl, -(C1-C3)alkyl-NH-C(O)O(C1-C6)alkyl or -NHC(O)R?15; R1, R2, R3 and R7¿ are H, alkyl, cycloalkyl, -CHF¿2?, -CH2F or -CF3; or R?1 and R2¿, together with the carbon to which they are attached, form an alkylene ring; or R?1 and R2¿ together are =O; R6 is R7 or -OH; and the remaining variables are as defined in the specification, methods of treating diseases susceptible to treatment with neurokinin antagonists with said compounds. Also disclosed are pharmaceutical compositions comprising an effective amount of a compound of claim 1, at least one pharmaceutically acceptable carrier, and in combination with an effective amount of a selective serotonin reuptake inhibitor. |